WHO Model List of Essential Medicines for Children

• Halothane
• Isoflurane
• Nitrous oxide
• Oxygen

• Ketamine
• PropofolThiopental may be used as an alternative depending on local availability and cost.

• Bupivacaine
• Lidocaine
• Lidocaine/epinephrine (lidocaine + epinephrine)

• Atropine
• Midazolam
• Morphine

• OxygenNo more than 30% oxygen should be used to initiate resuscitation of neonates less than or equal to 32 weeks of gestation.

• IbuprofenNot in children less than three months.
• ParacetamolNot recommended for anti‐inflammatory use due to lack of proven benefit to that effect. (acetaminophen)

• MorphineAlternatives limited to hydromorphone and oxycodone.
• Methadone{{ref|Alpha|α}}For the management of cancer pain.

• Amitriptyline
• Cyclizine
• Dexamethasone
• Diazepam
• Docusate sodium
• Fluoxetine
• Hyoscine hydrobromide
• Lactulose
• Midazolam
• OndansetronAlternatives limited to dolasetron, granisetron, palonosetron, and tropisetron
• Senna

• Dexamethasone
• Epinephrine (adrenaline)
• Hydrocortisone
• LoratadineAlternatives limited to cetirizine and fexofenadineThere may be a role for sedating antihistamines for limited indications.
• PrednisoloneAlternatives limited to prednisone

• Charcoal, activated

• Acetylcysteine
• Atropine
• Calcium gluconate
• Naloxone
• Deferoxamine{{ref|Alpha|α}}
• Dimercaprol{{ref|Alpha|α}}
• Fomepizole{{ref|Alpha|α}}
• Sodium calcium edetate{{ref|Alpha|α}}
• Succimer{{ref|Alpha|α}}

• Carbamazepine
• Diazepam
• LamotrigineFor use as adjunctive therapy for treatment-resistant partial or generalized seizures.
• LorazepamAlternatives limited to diazepam and midazolam
• MidazolamFor buccal administration when solution for oromucosal administration is not available.
• Phenobarbital
• PhenytoinThe presence of both 25 mg/5 mL and 30 mg/5 mL strengths on the same market would cause confusion in prescribing and dispensing and should be avoided.
• Valproic acid (sodium valproate)Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
• Ethosuximide{{ref|Alpha|α}}
• Valproic acid (sodium valproate){{ref|Alpha|α}}Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.

File:Albendazole.svg

• Albendazole
• Ivermectin
• Levamisole
• Mebendazole
• Niclosamide
• Praziquantel
• Pyrantel

• Albendazole
• Diethylcarbamazine
• Ivermectin

• Praziquantel
• Triclabendazole
• Oxamniquine{{ref|Alpha|α}}Oxamniquine is listed for use when praziquantel treatment fails.

• Albendazole{{ref|Alpha|α}}
• Mebendazole{{ref|Alpha|α}}
• Praziquantel{{ref|Alpha|α}}

• Amikacin
• Amoxicillin
• Amoxicillin/clavulanic acid (amoxicillin + clavulanic acid)
• Ampicillin
• Benzathine benzylpenicillin
• Benzylpenicillin
• Cefalexin
• Cefazolin> 1 month.
• ChloramphenicolOnly for the presumptive treatment of epidemic meningitis in children older than two years and in adults.
• Clindamycin
• CloxacillinAlternatives limited to 4th level ATC chemical subgroup (J01CF Beta-lactamase resistant penicillins)cloxacillin, dicloxacillin and flucloxacillin are preferred for oral administration due to better bioavailability.
• DoxycyclineUse in children <8 years only for life-threatening infections when no alternative exists.
• Gentamicin
• Metronidazole
• Nitrofurantoin
• Phenoxymethylpenicillin (penicillin V)
• Procaine benzylpenicillinProcaine benzylpenicillin is not recommended as first-line treatment for neonatal sepsis except in settings with high neonatal mortality, when given by trained health workers in cases where hospital care is not achievable.
• Sulfamethoxazole/trimethoprim (sulfamethoxazole + trimethoprim)
• Trimethoprim

• Azithromycin
• Cefixime
• CefotaximeThird-generation cephalosporin of choice for use in hospitalized neonates.
• CeftriaxoneDo not administer with calcium and avoid in infants with hyperbilirubinemia.> 41 weeks corrected gestational age.
• Cefuroxime
• Ciprofloxacin
• ClarithromycinErythromycin may be an alternative.
• Piperacillin/tazobactam (piperacillin + tazobactam)
• Vancomycin
• Ceftazidime{{ref|Alpha|α}}
• Meropenem{{ref|Alpha|α}}Imipenem/cilastatin is an alternative for complicated intraabdominal infections and high-risk febrile neutropenia only, except for acute bacterial meningitis in neonates, where meropenem is preferred
• Vancomycin{{ref|Alpha|α}}

Reserve antibiotics are last-resort antibiotics. The EML antibiotic book was published in 2022.{{Cite web |date=24 November 2021 |title=The WHO Essential Medicines List Antibiotic Book |url=https://www.who.int/news-room/questions-and-answers/item/the-who-essential-medicines-list-antibiotic-book |access-date=2022-10-06 |website=World Health Organization (WHO) |archive-date=11 November 2022 |archive-url=https://web.archive.org/web/20221111171654/https://www.who.int/news-room/questions-and-answers/item/the-who-essential-medicines-list-antibiotic-book |url-status=live }}{{cite book | title=The WHO AWaRe (Access, Watch, Reserve) antibiotic book | location=Geneva | publisher=World Health Organization (WHO) | year=2022 | url=https://www.who.int/publications/i/item/9789240062382 | access-date=29 January 2023 | isbn=978-92-4-006238-2 | archive-date=13 August 2023 | archive-url=https://web.archive.org/web/20230813134739/https://www.who.int/publications/i/item/9789240062382 | url-status=live }}{{cite book | title=The WHO AWaRe (Access, Watch, Reserve) antibiotic book - Infographics | location=Geneva | publisher=World Health Organization (WHO) | year=2022 | url=https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2022.02 | access-date=29 January 2023 | id=WHO/MHP/HPS/EML/2022.02 | archive-date=29 January 2023 | archive-url=https://web.archive.org/web/20230129194901/https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2022.02 | url-status=live }}

• Ceftazidime/avibactam (ceftazidime + avibactam){{ref|Alpha|α}}
• Colistin{{ref|Alpha|α}}
• Fosfomycin{{ref|Alpha|α}}
• Linezolid{{ref|Alpha|α}}
• Polymyxin B{{ref|Alpha|α}}

• Clofazimine
• Dapsone
• Rifampicin

File:Ethambutol substance photo.jpg

• Ethambutol
• Isoniazid
• Isoniazid/pyrazinamide/rifampicin (isoniazid + pyrazinamide + rifampicin)
• Isoniazid/rifampicin (isoniazid + rifampicin)
• Isoniazid/rifapentine (isoniazid + rifapentine)
• Pyrazinamide
• Rifampicin
• Rifapentine
• Amikacin{{ref|Alpha|α}}
• Amoxicillin/clavulanic acid (amoxicillin + clavulanic acid){{ref|Alpha|α}}For use only in combination with meropenem.
• Bedaquiline{{ref|Alpha|α}}
• Clofazimine{{ref|Alpha|α}}
• Cycloserine{{ref|Alpha|α}}Terizidone may be an alternative
• Delamanid{{ref|Alpha|α}}
• Ethionamide{{ref|Alpha|α}}Prothionamide may be used as an alternative.
• Levofloxacin{{ref|Alpha|α}}
• Linezolid{{ref|Alpha|α}}
• Meropenem{{ref|Alpha|α}}
• Moxifloxacin{{ref|Alpha|α}}
• P-aminosalicylic acid{{ref|Alpha|α}}
• Streptomycin{{ref|Alpha|α}}

• Amphotericin B
• Fluconazole
• Flucytosine
• Griseofulvin
• ItraconazoleFor treatment of chronic pulmonary aspergillosis, acute invasive aspergillosis, histoplasmosis, sporotrichosis, paracoccidiodomycosis, mycoses caused by T. marneffei and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by T. marneffei in AIDS patients.
• Nystatin
• VoriconazoleFor treatment of chronic pulmonary aspergillosis and acute invasive aspergillosis.
• Micafungin{{ref|Alpha|α}}Alternatives limited to anidulafungin and caspofungin
• Potassium iodide{{ref|Alpha|α}}

• Aciclovir

• Lamivudine
• Zidovudine

• Nevirapine

• Darunavir
• Lopinavir/ritonavir (lopinavir + ritonavir)
• Ritonavir

• Dolutegravir
• Raltegravirfor use in second-line regimens in accordance with WHO treatment guidelines

• Abacavir/lamivudine (abacavir + lamivudine)
• Lamivudine/zidovudine (lamivudine + zidovudine)

• Isoniazid/pyridoxine/sulfamethoxazole/trimethoprim (isoniazid + pyridoxine + sulfamethoxazole + trimethoprim)

• RibavirinFor the treatment of viral haemorrhagic fevers only.
• Oseltamivir{{ref|Alpha|α}}Severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients
• Valganciclovir{{ref|Alpha|α}}For the treatment of cytomegalovirus retinitis (CMVr).

• Entecavir

• DaclatasvirPangenotypic when used in combination with sofosbuvir
• Daclatasvir/sofosbuvir (daclatasvir + sofosbuvir)
• Glecaprevir/pibrentasvir (glecaprevir + pibrentasvir)
• SofosbuvirPangenotypic when used in combination with daclatasvir
• Sofosbuvir/velpatasvir (sofosbuvir + velpatasvir)

No listings in this section.

No listings in this section.

• Diloxanide
• MetronidazoleAlternatives limited to tinidazole

• Amphotericin B
• Miltefosine
• Paromomycin
• Sodium stibogluconate or meglumine antimoniate

• AmodiaquineTo be used in combination with artesunate 50 mg.
• ArtemetherFor use in the management of severe malaria.
• Artemether/lumefantrine (artemether + lumefantrine)Not recommended in the first trimester of pregnancy or in children below 5 kg.
• ArtesunateTo be used in combination with either amodiaquine, mefloquine or sulfadoxine + pyrimethamine.
• Artesunate/amodiaquine (artesunate + amodiaquine)Other combinations that deliver the target doses required such as 153 mg or 200 mg (as hydrochloride) with 50 mg artesunate can be alternatives.
• Artesunate/mefloquine (artesunate + mefloquine)
• Artesunate/pyronaridine tetraphosphate (artesunate + pyronaridine tetraphosphate)
• ChloroquineFor use only for the treatment of Plasmodium vivax infection.
• Dihydroartemisinin/piperaquine phosphate (dihydroartemisinin + piperaquine phosphate)
• DoxycyclineFor use only in combination with quinine.
• MefloquineTo be used in combination with artesunate 50 mg.
• PrimaquineOnly for use to achieve radical cure of Plasmodium vivax and Plasmodium ovale infections, given for 14 days.
• QuinineFor use only in the management of severe malaria, and should be used in combination with doxycycline.
• Sulfadoxine/pyrimethamine (sulfadoxine + pyrimethamine)Only in combination with artesunate 50 mg.

• Amodiaquine + sulfadoxine/pyrimethamine (Co-packaged)
• ChloroquineFor use only for the treatment of Plasmodium vivax infection.
• Doxycycline
• Mefloquine
• ProguanilFor use only in combination with chloroquine.
• Sulfadoxine/pyrimethamine (sulfadoxine + pyrimethamine)

• Pyrimethamine
• Sulfadiazine
• Sulfamethoxazole/trimethoprim (sulfamethoxazole + trimethoprim)

• FexinidazoleFor the treatment of 1st and 2nd stage of human African trypanosomiasis due to Trypanosoma brucei gambiense infection.

• PentamidineTo be used for the treatment of Trypanosoma brucei gambiense infection.
• Suramin sodiumTo be used for the treatment of the initial phase of Trypanosoma brucei rhodesiense infection.

• EflornithineTo be used for the treatment of Trypanosoma brucei gambiense infection
• NifurtimoxOnly to be used in combination with eflornithine, for the treatment of Trypanosoma brucei gambiense infection.
• Melarsoprol{{ref|Alpha|α}}

• Benznidazole
• Nifurtimox

• Ivermectin

• Ibuprofen
• Paracetamol

• Propranolol

• Adalimumab{{ref|Alpha|α}}etanercept and infliximab are alternatives, including quality-assured biosimilars
• Azathioprine{{ref|Alpha|α}}
• Ciclosporin{{ref|Alpha|α}}
• Tacrolimus{{ref|Alpha|α}}

• Arsenic trioxide{{ref|Alpha|α}}
• Asparaginase{{ref|Alpha|α}}
• Bleomycin{{ref|Alpha|α}}
• Calcium folinate{{ref|Alpha|α}}
• Carboplatin{{ref|Alpha|α}}
• Cisplatin{{ref|Alpha|α}}
• Cyclophosphamide{{ref|Alpha|α}}
• Cytarabine{{ref|Alpha|α}}
• Dacarbazine{{ref|Alpha|α}}
• Dactinomycin{{ref|Alpha|α}}
• Daunorubicin{{ref|Alpha|α}}
• Doxorubicin{{ref|Alpha|α}}
• Etoposide{{ref|Alpha|α}}
• Fluorouracil{{ref|Alpha|α}}
• Hydroxycarbamide{{ref|Alpha|α}}
• Ifosfamide{{ref|Alpha|α}}
• Irinotecan{{ref|Alpha|α}}
• Mercaptopurine{{ref|Alpha|α}}
• Methotrexate{{ref|Alpha|α}}
• Oxaliplatin{{ref|Alpha|α}}
• Paclitaxel{{ref|Alpha|α}}
• Pegaspargase{{ref|Alpha|α}}including quality-assured biosimilars
• Procarbazine{{ref|Alpha|α}}
• Realgar/Indigo naturalis{{ref|Alpha|α}}
• Tioguanine{{ref|Alpha|α}}
• Vinblastine{{ref|Alpha|α}}
• Vincristine{{ref|Alpha|α}}
• Vinorelbine{{ref|Alpha|α}}

• All-trans retinoid acid (ATRA){{ref|Alpha|α}}
• Dasatinib{{ref|Alpha|α}}
• Everolimus{{ref|Alpha|α}}
• Imatinib{{ref|Alpha|α}}
• Nilotinib{{ref|Alpha|α}}
• Rituximab{{ref|Alpha|α}}including quality-assured biosimilars

• Filgrastim{{ref|Alpha|α}}

• Dexamethasone{{ref|Alpha|α}}
• Hydrocortisone{{ref|Alpha|α}}
• Methylprednisolone{{ref|Alpha|α}}
• Prednisolone{{ref|Alpha|α}}Alternatives limited to prednisone

• Allopurinol{{ref|Alpha|α}}
• Mesna{{ref|Alpha|α}}
• Rasburicase{{ref|Alpha|α}}

• Ferrous salt
• Folic acid
• Hydroxocobalamin
• Erythropoiesis-stimulating agentsAlternatives limited to epoetin alfa, beta and theta, darbepoetin alfa, and their quality-assured biosimilars.

• EnoxaparinAlternatives are limited to nadroparin, dalteparin, and their quality-assured biosimilars.
• Phytomenadione
• Desmopressin{{ref|Alpha|α}}
• Heparin sodium{{ref|Alpha|α}}
• Protamine sulfate{{ref|Alpha|α}}
• Warfarin{{ref|Alpha|α}}

• Deferoxamine{{ref|Alpha|α}}Alternatives are limited to the oral form of deferasirox.
• Hydroxycarbamide{{ref|Alpha|α}}

File:FreshFrozenPlasma.JPG

• Fresh frozen plasma
• Platelets
• Red blood cells
• Whole blood

• Anti-rabies immunoglobulin
• Anti-tetanus immunoglobulin
• Normal immunoglobulin{{ref|Alpha|α}}

• Coagulation factor VIII{{ref|Alpha|α}}
• Coagulation factor IX{{ref|Alpha|α}}

• Dextran 70Polygeline, injectable solution, 3.5% is considered as equivalent.

No listings in this section.

No listings in this section.

• EnalaprilAlternatives limited to 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain)

• Digoxin
• Furosemide
• Dopamine{{ref|Alpha|α}}

No listings in this section.

No listings in this section.

• MiconazoleAlternatives limited to 4th level ATC chemical subgroup (D01AC Imidazole and triazole derivatives) excluding combinations
• Terbinafine

• Mupirocin
• Potassium permanganate
• Silver sulfadiazine

• BetamethasoneAlternatives limited to 4th level ATC chemical subgroup (D07AC Corticosteroids, potent (group III))
• Calamine
• Hydrocortisone

• Benzoyl peroxide
• CalcipotriolAlternatives limited to calcitriol and tacalcitol
• Coal tar
• Podophyllum resinAlternatives limited to podophyllotoxin
• Salicylic acid
• Urea

• Benzyl benzoateAlternatives limited to precipitated sulfur topical ointment
• Permethrin

• Fluorescein
• TropicamideAlternatives limited to atropine and cyclopentolate

• Barium sulfate{{ref|Alpha|α}}

• Chlorhexidine
• EthanolAlternatives limited to propanol
• Povidone iodineAlternatives limited to iodine

• Alcohol based hand rub
• Chlorine base compound
• ChloroxylenolAlternatives limited to 4th level ATC chemical subgroup (D08AE Phenol and derivatives)
• Glutaral

• Furosemide
• Hydrochlorothiazide{{ref|Alpha|α}}Alternatives limited to chlorothiazide and chlorthalidone
• Mannitol{{ref|Alpha|α}}
• Spironolactone{{ref|Alpha|α}}

• Pancreatic enzymes{{ref|Alpha|α}}

• OmeprazoleAlternatives limited to 4th level ATC chemical subgroup (A02BC Proton pump inhibitors) excluding combinations
• RanitidineAlternatives limited to 4th level ATC chemical subgroup (A02BA H2-receptor antagonists) excluding combinations

• Dexamethasone
• Metoclopramide
• Ondansetron
• Aprepitant{{ref|Alpha|α}}

No listings in this section.

No listings in this section.

• Oral rehydration salts + zinc sulfate (Co-packaged)

• Oral rehydration salts

• Zinc sulfateIn acute diarrhoea zinc sulfate should be used as an adjunct to oral rehydration salts

• Fludrocortisone
• Hydrocortisone

No listings in this section.

No listings in this section.

No listings in this section.

• Insulin injection (soluble)
• Intermediate-acting insulin
• Long-acting insulin analoguesAlternatives limited to insulin detemir, insulin degludec, and insulin glargine, including quality-assured biosimilars

• Metformin{{ref|Alpha|α}}

• Glucagon
• Diazoxide{{ref|Alpha|α}}

• Levothyroxine
• Lugol's solution{{ref|Alpha|α}}
• MethimazoleCarbimazole is an alternative depending on local availability.
• Potassium iodide{{ref|Alpha|α}}
• Propylthiouracil{{ref|Alpha|α}}For use when alternative first-line treatment is not appropriate or available

• Tuberculin, purified protein derivative (PPD)

• Anti-rabies virus monoclonal antibodies
• Antivenom immunoglobulinExact type to be defined locally.
• Diphtheria antitoxin
• Equine rabies immunoglobulin

Recommendations for all

• BCG vaccine
• Diphtheria vaccine
• Haemophilus influenzae type b vaccine
• Hepatitis B vaccine
• HPV vaccine
• Measles vaccine
• Pertussis vaccine
• Pneumococcal vaccine
• Poliomyelitis vaccine
• Rotavirus vaccine
• Rubella vaccine
• Tetanus vaccine

Recommendations for certain regions

• Japanese encephalitis vaccineRecommended for certain regions
• Yellow fever vaccine
• Tick-borne encephalitis vaccine

Recommendations for some high-risk populations

• Cholera vaccineRecommended for some high-risk populations
• Dengue vaccine
• Hepatitis A vaccine
• Meningococcal meningitis vaccine
• Rabies vaccine
• Typhoid vaccine

Recommendations for immunization programmes with certain characteristics

• Influenza vaccineRecommended for immunisation programmes with certain characteristics
• Mumps vaccine
• Varicella vaccine

• Neostigmine
• Suxamethonium
• Vecuronium
• Pyridostigmine{{ref|Alpha|α}}

• Aciclovir
• Azithromycin
• ErythromycinInfections due to Chlamydia trachomatis or Neisseria gonorrhoeae.
• GentamicinAlternatives limited to amikacin, kanamycin, netilmicin, and tobramycin
• Natamycin
• OfloxacinAlternatives limited to 4th level ATC chemical subgroup (S01AE Fluoroquinolones)
• TetracyclineAlternatives limited to chlortetracycline and oxytetracycline

• Prednisolone

• TetracaineAlternatives limited to 4th level ATC chemical subgroup (S01HA Local anaesthetics) excluding cocaine and combinations

No listings in this section.

• AtropineAlternatives limited to homatropine hydrobromide or cyclopentolate hydrochloride.
• Epinephrine (adrenaline){{ref|Alpha|α}}

No listings in this section.

No listings in this section.

No listings in this section.

No listings in this section.

No listings in this section.

No listings in this section.

• Caffeine citrate
• Chlorhexidine
• Ibuprofen{{ref|Alpha|α}}Alternatives limited to indometacin
• Prostaglandin E1{{ref|Alpha|α}}Alternatives limited to prostaglandin E2
• Surfactant{{ref|Alpha|α}}

• Intraperitoneal dialysis solution (of appropriate composition){{ref|Alpha|α}}

• Chlorpromazine{{ref|Alpha|α}}
• Haloperidol{{ref|Alpha|α}}

• Fluoxetine{{ref|Alpha|α}}

No listings in this section.

No listings in this section.

No listings in this section.

No listings in this section.

• BudesonideAlternatives limited to beclometasone, ciclesonide, flunisolide, fluticasone, and mometasone
• Epinephrine (adrenaline)
• Salbutamol (albuterol)Alternatives limited to terbutaline

• Oral rehydration salts
• Potassium chloride

• Glucose
• Glucose with sodium chloride
• Potassium chloride
• Sodium chloride
• Sodium hydrogen carbonate
• Sodium lactate, compound solution

• Water for injection

• Ascorbic acid
• CholecalciferolErgocalciferol can be used as an alternative.
• Iodine
• Multiple micronutrient powder
• Pyridoxine
• Retinol
• Riboflavin
• Thiamine
• Calcium gluconate{{ref|Alpha|α}}

• Acetic acid
• Budesonide
• CiprofloxacinAlternatives limited to ofloxacin
• Xylometazoline

No listings in this section.

• Hydroxychloroquine{{ref|Alpha|α}}
• Methotrexate{{ref|Alpha|α}}

• Aspirin{{ref|Alpha|α}}For use for rheumatic fever, juvenile arthritis, Kawasaki disease

• Fluoride
• Glass ionomer cement
• Silver diamine fluoride

{{Reflist|group=note}}

{{reflist}}

• {{cite book | vauthors=((World Health Organization)) | title=The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children) | year=2015 | publisher=World Health Organization | author-link = World Health Organization | isbn=9789240694941 | hdl=10665/189763 | issn=0512-3054 | location=Geneva | id=WHO technical report series; no. 994 | hdl-access=free }}
• {{cite book | vauthors = ((World Health Organization)) | title=The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children) | author-link = World Health Organization | year=2017 | publisher=World Health Organization | isbn=978-92-4-121015-7 | hdl=10665/259481 | issn=0512-3054 | location=Geneva | id=WHO technical report series; no. 1006 | hdl-access=free }}
• {{cite book | vauthors = ((World Health Organization)) | year = 2019 | title = The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children) | publisher = World Health Organization | location = Geneva | author-link = World Health Organization | hdl = 10665/330668 | id = WHO technical report series;1021 | hdl-access=free | isbn = 9789241210300 | issn = 0512-3054 }}

{{URL|https://list.essentialmeds.org/|eEML - Electronic Essential Medicines List }}

{{Portal bar|Politics|Medicine|Viruses}}

{{DEFAULTSORT:Who Model List Of Essential Medicines For Children}}

Children

Category:2007 introductions

Category:Drug-related lists